Performance analysis of Atrium Therapeutics (RNA)
Annual Return
Since Feb 27, 2026, RNA has had an average annual return of -16.68%, underperforming the benchmark SPY, which returned +9.67% annual.
| 2026 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -16.68% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0% | -9.36% | -4.48% | +1.80% | +3.46% | -8.63% | -16.68% |
Drawdown analysis of Atrium Therapeutics (RNA)
The maximum drawdown for the RNA was -30.17%, occurring on Jun 8, 2026. This drawdown has not yet recovered.
The current RNA drawdown is -25.70%.
Since Feb 27, 2026 RNA has experienced the following drawdowns:
- 30% or more: 1 time
- 20% or more: 1 time
- 10% or more: 1 time
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -30.17% | Mar 4, 2026 | 66 | Jun 8, 2026 | Ongoing | Ongoing | Ongoing |